FDA Approves Companion Diagnostic for IDH1-Mutated Cholangiocarcinoma

On August 25, 2021, the U.S. Food and Drug Administration (FDA) granted pre-market approval to Oncomine Dx Target Test as a companion diagnostic to identify patients with isocitrate dehydrogenase-1 (IDH1) mutated cholangiocarcinoma who may be candidates for Tibsovo® (ivosidenib) (Servier Pharmaceuticals).

Read the Thermo Fisher Scientific announcement.

Posted 8/27/2021